Even though there are still many questions to comprehend the mechanism of pirenperone as a potential drug candidate for FXS, we assume that the current study will provide new insights into discovering effective drug candidates for the disorder and also the possibility that 5-HT2A modulators can be drug targets for FXS. Here, HTR2A is linked to fragile X syndrome.